KNC LABORATORIES CO LTD has a total of 13 patent applications. It increased the IP activity by 50.0%. Its first patent ever was published in 2015. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets biotechnology, organic fine chemistry and pharmaceuticals are MATSUO MASAFUMI, SUZHOU RIBO LIFE SCIENCE CO LTD and NANODOC LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 8 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | United States | 2 | |
#4 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Organic fine chemistry | |
#3 | Pharmaceuticals | |
#4 | Foods and drinks | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Fermentation | |
#3 | Medical preparations | |
#4 | Sugars | |
#5 | Special acyclic compounds | |
#6 | Climate change mitigation in goods production | |
#7 | Fodder | |
#8 | Therapeutic chemical compounds | |
#9 | Foods | |
#10 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Matsuo Masafumi | 5 |
#2 | Neya Masahiro | 4 |
#3 | Fujihara Tsuyoshi | 4 |
#4 | Suzuki Munenori | 3 |
#5 | Nakamura Kenichi | 3 |
#6 | Matsuda Seiji | 3 |
#7 | Kurome Toru | 3 |
#8 | Sasahara Daisuke | 3 |
#9 | Shimahara Akiko | 3 |
#10 | Maeta Kazuhiro | 2 |
Publication | Filing date | Title |
---|---|---|
WO2021045141A1 | Oligonucleotide deprotection method | |
WO2020262184A1 | Nucleic acid drug suppressing production of myostatin gene mrna | |
WO2020179571A1 | Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereof | |
WO2019163601A1 | Transgenic plant and use thereof | |
WO2019131719A1 | Production of highly fat-soluble phosphoramidite | |
WO2018138966A1 | Transformant and use thereof | |
WO2017130716A1 | Novel taxadiene oxidase and utilization thereof | |
WO2017047651A1 | Transformant, and terpenoid production method | |
CA2948139A1 | Nucleic acid drug for inducing skipping of variant exon of cd44 gene and increasing expression of normal type cd44 mrna |